Standout Papers

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-bl... 2016 2026 2019 2022 327
  1. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial (2016)
    Fred Lublin, David H. Miller et al. The Lancet

Immediate Impact

2 by Nobel laureates 8 from Science/Nature 80 standout
Sub-graph 1 of 19

Citing Papers

IL-10 constrains sphingolipid metabolism to limit inflammation
2024 StandoutNature
STING orchestrates the neuronal inflammatory stress response in multiple sclerosis
2024 Standout
15 intermediate papers

Works of Norman Putzki being referenced

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
2018
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
2016 Standout
and 8 more

Author Peers

Author Last Decade Papers Cites
Norman Putzki 1504 649 384 46 2.1k
Martin Gunnarsson 1368 639 426 46 2.0k
Ali Manouchehrinia 1488 486 253 72 2.0k
Ilya Kister 1937 957 330 107 2.6k
D. H. Silberberg 1119 570 305 45 2.4k
Frank Dahlke 1834 766 389 74 2.4k
Ludwig Kappos 956 473 343 58 1.6k
Dusan Stefoski 1684 633 581 56 2.7k
Ingrid Galán 1534 622 339 39 1.8k
Enrico Millefiorini 1401 688 341 62 1.9k
Antonio Scalfari 1621 561 328 44 1.9k

All Works

Loading papers...

Rankless by CCL
2026